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ttp://dx.doi.org/10.1016/j.ajpath.2014.12.014Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a pan-ErbB negative regulator and
intestinal stem cell marker down-regulated in many malignancies. We previously reported that 14 of 16
Lrig1-CreERT2/CreERT2 (Lrig1/) mice developed duodenal adenomas, providing the ﬁrst in vivo evi-
dence that Lrig1 acts as a tumor suppressor. We extended this study to a larger cohort and found that
49 of 54 Lrig1/ mice develop duodenal adenomas beginning at 3 months. Most adenomas were
histologically low grade and overlaid expanded Brunner glands. There was morphologic and
biochemical blurring of the boundary between the epithelium and Brunner glands with glandular
coexpression of ErbB2, which is normally restricted to the epithelium, and the Brunner gland marker
Mucin6. Some adenomas were high grade with reduced Brunner glands. At age 4 to 5 weeks, before
adenoma formation, we observed enhanced proliferation in Brunner glands and, at 2 months, an in-
crease in the size of the Brunner gland compartment. Elevated expression of the epidermal growth
factor receptor (Egfr) ligands amphiregulin and b-cellulin, as well as Egfr and phosphorylated Egfr, was
detected in adenomas compared with adjacent normal tissue. These adenomas expressed the gastric-
speciﬁc genes gastrokine1 and mucin5ac, indicating gastric metaplasia. Moreover, we found that a
subset of human duodenal tumors exhibited features of LRIG1/ adenomas, including loss of LRIG1,
gastric metaplasia (MUCIN5AC and MUCIN6), and increased amphiregulin and Egfr activity.
(Am J Pathol 2015, 185: 1123e1134; http://dx.doi.org/10.1016/j.ajpath.2014.12.014)Supported in part by National Cancer Institute grants CA46413 and
CA151566, Gastrointestinal Specialized Program of Research Excellence
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Disclosures: None declared.The ERBB family of receptor tyrosine kinases includes
epidermal growth factor receptor (EGFR, or ERBB1) and
ERBB2-4.1e3 Seven mammalian ligands bind EGFR: EGF,
transforming growth factor-a, heparin-binding EGF-like
growth factor, amphiregulin (AREG), epiregulin, beta-
cellulin (BTC), and epigen.4 ERBB signaling plays critical
roles during the development and maintenance of homeo-
stasis in adult tissues. Precise regulation of signaling is
required to ensure the ﬁdelity of these processes, especially
because EGFR activation induces transcription of EGFR
and its ligands in a positive feedback manner.5,6 Loss of
ERBB negative regulation as a mechanism of aberrant
ERBB activation is beginning to be appreciated as a
hallmark of cancers.7,8
Leucine-rich repeats and immunoglobulin-like domains 1
(LRIG1), a pan-ERBB negative regulator, is a transmembranestigative Pathology.
.protein that down-regulates EGFR signaling by accelerating
receptor internalization and degradation in a c-CBLe
dependent manner.9,10 Reduced expression of LRIG1 has
been reported in breast,11,12 cervical,13 and skin cancers,14 as
recently reviewed by Wang et al9 and Hedman and col-
leagues.15 In addition, the soluble ectodomain of LRIG1 in-
hibits in vivo growth of EGFRVIII mutant gliomas,16 and
restoration of LRIG1 expression sensitizes glioma cells to
chemotherapy.17
Wang et alWe recently showed that Lrig1 marks a distinct population
of stem cells in the small and large intestines and that the
genetic ablation of Lrig1 resulted in duodenal adenomas in 14
of 16 mice.18 We now show that 49 of 54 Lrig1-CreERT2/
CreERT2 (hereafter referred to as Lrig1/) mice developed
duodenal adenomas beginning at 3 months of age. Moreover,
we provide a detailed histologic, molecular, and biochemical
characterization of these adenomas. We found that loss of
Lrig1 results in highly penetrant duodenal adenomas with
gastric metaplasia and increased ErbB signaling. In addition,
we identiﬁed a subset of previously unrecognized human
duodenal adenomas and carcinomas that also have
dysplastic Brunner glands, gastric metaplasia, heightened
EGFR signaling, and reduced LRIG1 immunoreactivity.
Materials and Methods
Animal Studies
The generation of Lrig1tm1.1(cre/ERT)Rjc (Lrig1-CreERT2) mice
was described elsewhere.18 Lrig1/ (homozygous Lrig1-
CreERT2) mice and wild-type littermates were maintained
on a 129S7/SvEv and C57BL/6 mixed background. Lrig1-
CreERT2/CreERT2;RosaR26R-EYFP/EYFP (cis) mice were
obtained by intercrossing Lrig1-CreERT2/þ;RosaR26R-
EYFP/þ (cis) mice. The Lrig1 and Rosa26R loci are 18 Mb
apart on chromosome 6. During extensive mating, a rare
crossover event occurred, which resulted in the engineered
loci residing in cis and cosegregating in subsequent progeny.
I.P. injection of 2 mg of tamoxifen dissolved in corn oil at 4
weeks of age was used to initiate lineage tracing to assess the
contribution of cells with Lrig1 loss in tumorigenesis. Freshly
dissected mouse duodenum was ﬁxed in 4% para-
formaldehyde overnight at 4C, followed by dehydration and
parafﬁn embedding. All the animal studies were approved by
the Division of Animal Care at Vanderbilt University
(Nashville, TN).Table 1 Quantitative RT-PCR Primer Information
Gene Forward primer
Areg 50-AACGGTGTGGAGAAAAATCC-30
Btc 50-GTGTGGTAGCAGATGGGAAC-30
Hbegf 50-GAGCAACAGAGCTGAGAAGC-30
Ereg 50-AACTGTTCACCAACCCTTGA-30
Egf 50-TTGTTAGCACCATCCCTCAT-30
Tgfa 50-CACTGGACTTCAGCCCTCTA-30
Epn 50-CCAATGGAGATCTTTGGATG-30
Egfr 50-GTGATGGGGATGTGATCATT-30
ErbB2 50-GCCCTCATCACCTACAACAC-30
ErbB3 50-GGCTACGACTGGCTGAAATA-30
ErbB4 50-GGACCCACAGAAAATCACTG-30
Tff1 50-GGAGAGAGGTTGCTGTTTTG-30
Tff2 50-TGCTTTGATCTTGGATGCTG-30
Gkn1 50-AGATTCCAGGACCAAACCAG-30
Gkn2 50-ACAGTGACCATCGACAACCA-30
Gkn3 50-AATACGGAGTGCCAATCAAA-30
1124Human Tissues
Pathology slides of human duodenal/ampullary adenomas
(nZ 27, from 2007 to 2012) and adenocarcinomas (nZ 61,
from 1994 to 2012) from the Vanderbilt University pathol-
ogy archives were reviewed. Five adenocarcinomas and
three adenomas meeting the following criteria were further
analyzed: occurring in the periampullary duodenum, pres-
ence of dysplastic Brunner glands, and CDX2 negativity by
immunohistochemical (IHC) analysis. Use of human tissues
was approved by the Vanderbilt University Institutional
Review Board.
Histologic, IHC, and Immunoﬂuorescence Analysis
Histologic analysis and immunostaining were performed on
5-mm sections. Brieﬂy, antigen retrieval was performed in
Target retrieval buffer (pH, 6; Dako, Carpinteria, CA) in an
automated pressure cooker for 15 minutes on high pressure for
all antibodies unless otherwise speciﬁed. For ErbB2 and phos-
phorylatedEGFR (p-EGFR) IHC analysis, antigen retrievalwas
performed in Target retrieval buffer (pH, 9; Dako). For IHC
analysis, anti-rabbit and anti-mouse polymers (Dako) were used
for secondary antibody detection and peroxidase visualization.
For immunoﬂuorescence, Alexa Fluor 488econjugated or
Alexa Fluor 568econjugated goateanti-rabbit/mouse sec-
ondary antibodies (Life Technologies, Grand Island, NY)were
used for visualization. Primary antibodies included antie
p-EGFR pY1068 (dilution 1:500; Epitomics Inc., Burlingame,
CA), anti-ERBB2 (dilution 1:700; Cell Signaling Technology
Inc., Danvers, MA), anti-Muc6 (dilution 1:100; Kanto
Chemical Co. Inc., Tokyo, Japan), anti-MUC6 (dilution 1:200;
Novocastra, Buffalo Grove, IL), anti-Muc5ac (dilution 1:500;
NeoMarkers, Fremont, CA), anti-MUC5AC (dilution 1:300;
Thermo Scientiﬁc, Waltham, MA), anti-Gastrokine1 (dilution
1:500; Abcam Inc., Cambridge, MA), anti-AREG (dilution
1:100; Lab Vision, Fremont, CA), antieKi-67 (dilution 1:200;Reverse primer
50-TTGTCCTCAGCTAGGCAATG-30
50-ATCTCCCATGGATGCAGTAA-30
50-TATTTTCCCCCTCTGGGTAG-30
50-CCTTGTCCGTAACTTGATGG-30
50-CGGGAGAGTTCTTTGTCTCA-30
50-TCCAGCAGACCAGAAAAGAC-30
50-TCTTCCTGCAGTGACAACAA-30
50-AGCATAAAGGATTGCAGACG-30
50-CTCAGCTGTGACCTCTTGGT-30
50-CGCTCTCTTGATGACCAGAT-30
50-TGTTCCAGTTGAAAGGTGGT-30
50-TCTGAGGGGTTGAACTGTGT-30
50-GGAAAAGCAGCAGTTTCGAC-30
50-ACAACCCCCAGAGAACACTC-30
50-AACCGTTGGAGTTTGTCCAG-30
50-ACACTTCTCACAGGCAGAGG-30
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Figure 1 Representative histologic features of Lrig1/ duodenal ade-
nomas. A: Hematoxylin and eosin (H&E) staining of a less advanced duodenal
adenoma from a 14-month-old Lrig1/ mouse. The adenoma contained
multiple cystically dilated glands and overlaid an expanded but histologically
normal Brunner gland region. B: Magniﬁcation of the boxed region in A
showing a blurring of the boundary between the overlying epithelium and
Brunner glands, with features of both compartments in this transition zone. A
cystically dilated gland containing both low-grade adenomatous features with
nuclear enlargement and hyperchromasia (black arrow) and relatively normal
Brunner gland cells (black arrowhead). C: H&E of an adenoma with more
advanced dysplastic features from a 5-month-old Lrig1/ mouse. The
dysplastic cells extended deeper into the Brunner gland compartment. D: A
high-power view of the boxed region in C showing an adenomatous glandwith
nuclear enlargement and an increased nuclear/cytoplasmic ratio (black arrow)
with adjacent small adenomatous glands composed of cuboidal epithelium
(black arrowhead). E: H&E of a high-grade adenoma from a 14-month-old
Lrig1/ mouse with increased cytologic atypia and greater architectural
complexity. F: A high-power view of the boxed region in E showing back-to-
back (cribriform) glands and a gland containing necrotic debris in its lumen
(white arrow). Scale bars: 100 mm. Original magniﬁcation: 3.8 (B).
Loss of Lrig1 Leads to Duodenal AdenomasDako), anti-MUC2 (dilution 1:100; Santa Cruz Biotech-
nology, Dallas, TX), anti-Lrig1 (dilution 1:100; R&D Sys-
tems, Minneapolis, MN), anti-LRIG1 (dilution 1:100;
Agrisera AB, Vännäs, Sweden), and anti-EGFP (dilution
1:500; Life Technologies).
To quantify Ki-67 positivity, all Ki-67þ cells in Brunner
glands were automatically counted by a Leica image viewer
(Leica Microsystems GmbH, Wetzlar, Germany) and divided
by the total number of Brunner glands in a given section. To
measure the size of Brunner glands in mouse duodenum,
approximately 2 cm of the very proximal duodenum
(including approximately 0.5 cm of the antrum) was cut open
longitudinally, ﬁxed with 4% paraformaldehyde, and
embedded on its edge in parafﬁn. For every 100-mm thickness,
a 5-mm section was cut until tissue was exhausted. All the
sections were hematoxylin and eosin stained and then scanned
with an Ariol SL-50 automated scanning microscope (Leica
Microsystems GmbH), with the area of the Brunner gland
compartment manually drawn and calculated by Digital Image
Hub software version 4.0.4 (Leica Microsystems GmbH). A
section that encompassed the medial area was chosen from
each animal to calculate the average size of Brunner glands
from each genotype. Brightﬁeld IHC images were scanned
using the Leica SCN400 slide scanner (Leica Microsystems
GmbH), and immunoﬂuorescence images were either scanned
using the Ariol SL-50 automated scanning microscope or
taken with an Olympus FV1000 inverted confocal microscope
(Olympus America Inc., Pittsburgh, PA).
Microarray Analysis and RT-qPCR
Full thicknesses of fresh duodenal adenoma (approximately 0.5
to 0.7 cm in longitudinal length), adjacent normal duodenum
distal to adenoma (approximately 0.7 cm in longitudinal
length), and wild-type proximal duodenum (approximately 0.7
cm in longitudinal length, equivalent to the position of ade-
nomas in Lrig1 null mice) were snap frozen in liquid nitrogen
and ground using an electronic grinder (A. Daigger & Co. Inc.,
Vernon Hills, IL). Total RNA was extracted using an RNeasy
micro kit (Qiagen Inc., Maryland, VA). Gene proﬁling was
performed on Affymetrix Mouse Gene 1.0 ST Array (Affy-
metrix, Santa Clara, CA) by VANTAGE (Vanderbilt Univer-
sity). Microarray data have been deposited in the National
Center for Biotechnology Information’s Gene Expression
Omnibus19 (http://www.ncbi.nlm.nih.gov/geo; Accession
number GSE64640). For quantitative RT-PCR (RT-qPCR),
cDNA was generated using SuperScript II Reverse Transcrip-
tase (Life Technologies). RT-qPCRwas performed in triplicate
on a StepOnePlus real-time PCR system (Applied Biosystems,
Grand Island, NY) and repeated three times. Each 20-mL
reaction contained 0.1 mmol/L primers, 4 mmol/L MgCl2, and
EXPRESS SYBR GreenER Supermix with premixed ROX
(Life Technologies). RT-qPCR reactions were performed
under the following conditions: 50C for 2 minutes, 95C for 2
minutes, followed by 40 cycles at 95C for 15 seconds and
58C for 45 seconds, after which a melting curve wasThe American Journal of Pathology - ajp.amjpathol.orgperformed to ensure the speciﬁcity of the PCR products.
Results were analyzed using the DDCT method. All the primer
sets (Table 1) except Tff2 (a gift from James R. Goldenring,
Vanderbilt University Medical Center) were purchased from
RealTimePCR.com (Cambridge, UK) and were validated
using relative standard curve methods followed by a melting
curve before applying to experimental samples.
Statistical Analysis
Data are presented as means  SEM. The unpaired Stu-
dent’s t-test was used to determine statistical signiﬁcance,
with a cutoff value of P < 0.05. All the graphs and statistical
analyses were performed using Prism 6 software (GraphPad
Software Inc., San Diego, CA).1125
Figure 2 Loss of Lrig1 promotes Brunner gland proliferation and
expansion before adenoma formation. A and B: Ki-67 immunohistochemical
analysis demonstrated signiﬁcantly more proliferative cells in Brunner
glands of a 4-week-old Lrig1/ mouse (B) compared with an age-matched
wild-type (WT) mouse (A). C: The mean number of Ki-67þ cells per gland is
similar at 3 weeks of age. This number increased at 4 and 5 weeks of age in
Lrig1/ mice but decreased at these times in WT mice. D: The size of the
Brunner gland compartment in 2-month-old Lrig1/ mice (n Z 5) is 1.5-
fold greater than that in age-matched WT mice (n Z 10). E and G: He-
matoxylin and eosin (H&E) demonstrates enlargement of the Brunner gland
region in an Lrig1/ mouse compared with a WT control. F and H: Muc6
immunoreactivity is conﬁned to Brunner glands in WT and Lrig1/ mice.
Data are given as means  SEM. *P < 0.05. Scale bars: 100 mm.
Figure 3 Blurring of the boundary between early adenoma and underlying
Brunner glands. A and B: Immunohistochemical analysis for ErbB2 (A) in the
overlying early adenoma and Muc6 (B) in Brunner glands. The transition zones
between the two compartments are boxed and magniﬁed in the insets. These
glands show partial staining for ErbB2 and Muc6. C: Immunoﬂuorescence
shows co-staining for ErbB2 (red) and Muc6 (green) in the same glands
(indicated bywhite dashed lines). D and E: Individual staining for ErbB2 and
Muc6. Scale bars: 100 mm. Original magniﬁcation: 2.5 (insets, B and C).
Wang et alResults
Loss of Lrig1 Leads to Duodenal Adenomas Overlying
an Expanded Brunner Gland Compartment
We previously reported that 14 of 16 Lrig1/ mice (88%)
developed spontaneous duodenal adenomas.18 Herein we
extended this analysis to show that 49 of 54 Lrig1/ mice1126(91%) developed adenomas in the proximal duodenum,
with adenomas ﬁrst noted at 3 months of age. The histo-
logic features of these adenomas vary; representative fea-
tures are shown in Figure 1 and Supplemental Figure S1.
Most of the adenomas were histologically low grade,
overlying an expanded Brunner gland compartment
(Figure 1, A and C). Cystically dilated glands were often
seen (Figure 1, B and D). These lesions also contained
cuboidal epithelial cells (Figure 1D). In low-grade lesions,
the boundary between Brunner glands and the overlying
epithelium was blurred, with a mixture of normal Brunner
gland cells, cuboidal Brunner gland cells with nuclear
enlargement, and slightly cuboidal cells with hyper-
chromatic nuclei and a higher nuclear/cytoplasmic ratio
coexisting in the same gland in this transition zoneajp.amjpathol.org - The American Journal of Pathology
Loss of Lrig1 Leads to Duodenal Adenomas(Figure 1B). More advanced lesions exhibited increased
basophilia, marked nuclear atypia, complex glandular ar-
chitecture, and dysplastic glands with necrotic debris
(Figure 1F); expansion of Brunner glands seemed less or
completely absent in these advanced lesions (Figure 1E).
Occasionally, lobules of histologically abnormal Brunner
glands with larger nuclei and reduced mucin were
observed (Supplemental Figure S1A). Tubular adenomas
were sometimes found in the duodenum distal to Brunner
glands (Supplemental Figure S1, BeD).
To study the pathogenesis of these duodenal adenomas, we
examined the histologic features of the proximal duodenum
before adenoma formation. In wild-type and Lrig1/ mice,
Brunner glands were present at birth, and there was Ki-67
immunoreactivity throughout the glands (Figure 2, A and B,
and data not shown). In wild-type mice, Ki-67 positivity,
indicating actively dividing cells, decreased after 3 weeks of
age (Figure 2C), and there was little, if any, Ki-67 immuno-
reactivity at 2 months (data not shown). Ki-67 immunoreac-
tivity was similar in wild-type and Lrig1/mice at 3 weeks of
age (Figure 2C and Supplemental Table S1). However, the
number of Ki-67þ positive cells was increased in Lrig1/
mice at 4 and 5 weeks of age; there were approximately
threefold more Ki-67þ cells in Lrig1/ mice compared with
wild-type mice at 5 weeks (P < 0.05) (Figure 2C). Therefore,
these data suggest that Brunner gland proliferation persists in
mice lacking Lrig1 in early adulthood.
At 2 months of age, but not before, we observed a 1.5-fold
increase in the size of Brunner glands in Lrig1/ miceThe American Journal of Pathology - ajp.amjpathol.orgcompared with age-matched wild-type controls (P < 0.05)
(Figure 2, DeH), presumably due to the heightened prolifer-
ation observed at 4 and 5 weeks of age. Brunner glands are
secretory glands located in the submucosa of the proximal
duodenum that secrete bicarbonate and mucin to neutralize
acidic contents from the stomach. Brunner glands and the
overlying epithelium form two histologically discrete com-
partments. Brunner glands contain acinar-like cells with small
nuclei, whereas the overlying epithelium is composed of
typical columnar epithelial cells with larger elongated nuclei.
In the normal intestine, Muc6 was found exclusively in
Brunner glands (Figure 2F), and ErbB2 staining was restricted
to the overlying epithelium (Supplemental Figure S2B).20
However, in less advanced lesions from Lrig1/ mice,
ErbB2 and Muc6 were coexpressed in the same gland in this
blurred boundary (Figure 3), suggesting abnormalities in
epithelial lineage allocation. Of note, surface erosions were not
observed in normal mucosa or in tumors of younger mice
(Supplemental Figure S1E), suggesting that adenoma forma-
tion is not a reactive process to gastric acidity.
Lrig1 protein was expressed in overlying epithelium and
Brunner glands (Figure 4A). When Lrig1/ mice on a
Rosa26R-EYFP background (Lrig1-CreERT2/CreERT2;
Rosa26R-EYFP/EYFP) were lineage traced with a single
tamoxifen induction at 4 weeks of age, a signiﬁcant portion
of the duodenal adenoma displayed YFP immunoreactivity
(Figure 4, BeD), suggesting that progenitor cells lacking
Lrig1 in both compartments contribute to adenoma
formation.Figure 4 Lrig1 is expressed in both Brunner
glands (BGs) and overlying epithelium (OE), and
Lrig1þ cells contribute to tumorigenesis by lineage
tracing. A: Immunoﬂuorescence showing Lrig1
(green) expressed in BGs and OE (of which the two
compartments were divided by white dashed
lines). B: Green ﬂuorescent protein (GFP) immu-
noﬂuorescence in a duodenal adenoma from an
Lrig1-CreERT2/CreERT2;Rosa26R-EYFP/EYFP mouse
that was lineage traced for 4 months from 4 weeks
of age. DAPI, blue; GFP, white (to visualize EYFP).
C andD:Boxed regions inB aremagniﬁed. Scale bars:
100 mm. Original magniﬁcation: 5 (C and D).
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Figure 5 Duodenal adenomas (Duo Ts) in Lrig1/ mice exhibit heightened epidermal growth factor receptor (Egfr) signaling. A: The Egfr ligands
amphiregulin (Areg) and betacellulin (Btc) were up-regulated by 10- and 13-fold, respectively, in the Duo Ts by quantitative RT-PCR. B: Egfr is the only ErbB
family member whose expression was signiﬁcantly up-regulated. CeE: Areg immunoreactivity is similar in Brunner glands from wild-type (WT) (C) and Lrig1/
(D) mice. However, Areg immunoreactivity is increased in the Duo T (E). FeH: Immunoﬂuorescence for phosphorylated Egfr (p-Egfr) (pY1068) showed
enhanced Egfr activity in an Lrig1/ Duo T, both in the adenomatous region (F) and at the adenoma periphery (G); minimal signal was detected in adjacent
normal (Adj NL) duodenal tissue (H). Confocal images were taken with the same exposure and laser voltage settings. Data are given as mean  SEM. The
unpaired Student’s t-test was used on each individual transcript. *P < 0.05. Scale bars: 30 mm (CeE); 50 mm (FeH).
Wang et alLrig1/ Duodenal Adenomas Overexpress Egfr Ligands
and Have Increased Egfr Activity
Brunner glands express EGF in humans21,22 and Egf and
Tgfa in rats.23 This prompted us to examine the expression1128of ErbBs and their cognate ligands in normal mouse duo-
denum and to compare these results with those in duodenal
adenomas and adjacent normal mucosa from Lrig1/ mice.
We found signiﬁcant up-regulation of Areg, Btc, and Egfr
expression by RT-qPCR in Lrig1/ duodenal adenomasajp.amjpathol.org - The American Journal of Pathology
Figure 6 Duodenal adenomas (Duo Ts) in Lrig1/ mice express gastric-speciﬁc markers. A: Heat map of genes up-regulated fourfold and greater in Duo Ts
compared with adjacent normal (Adj NL) tissues by gene proﬁling. B: Bar graph of the fold change in gene expression from A. C: Gastric-speciﬁc genes are
signiﬁcantly up-regulated by quantitative RT-PCR: Tff1 (gastric foveolar cells), Tff2 (antral glands and Brunner glands), Gkn1 (gastric foveolar cells), Gkn2
(gastric foveolar cells), and Gkn3 (antral glands). D: A proximal Duo T overlying expanded Brunner glands (marked by white dotted lines) was largely negative
for Cdx2 immunoreactivity, whereas an adjacent tubular adenoma distal to Brunner glands exhibited Cdx2 immunoreactivity. E: A proximal Duo T with absence
of Cdx2 immunoreactivity at high power. F and G: Representative immunoﬂuorescence for Muc5ac and immunohistochemical staining for Gkn1, indicating the
presence of gastric foveolar cells in Lrig1/ Duo Ts. Data are given as means  SEM. Scale bars: 100 mm (D, E, and G); 25 mm (F).
Loss of Lrig1 Leads to Duodenal Adenomascompared with grossly normal adjacent tissue and wild-type
duodenum (Figure 5, A and B). Likewise, Areg immuno-
ﬂuorescence was more intense in Lrig1/ duodenal ade-
nomas (Figure 5E and Supplemental Figure S3A) compared
with wild-type duodenum (Figure 5C) and adjacent normal
duodenum (Figure 5D). Areg staining intensity was similar
in wild-type Brunner glands (Figure 5C) and histologically
normal Brunner glands underneath Lrig1/ adenomas
(Figure 5D). There was low, but detectable, Egf expression
in the duodenum by RT-qPCR (Figure 5, A and B); how-
ever, we did not detect Egf immunoreactivity (data not
shown). There was also increased p-Egfr immunoreactivity
in cystically dilated glands with dysplastic cuboidal-shaped
cells (Figure 5F) and at the adenoma periphery (Figure 5G)The American Journal of Pathology - ajp.amjpathol.orgcompared with grossly normal epithelium (Figure 5H),
indicating that Egfr is activated in these adenomas.
Together, these data suggest that loss of Lrig1 leads to up-
regulation of Egfr ligands and activation of Egfr, thus
supporting a role for enhanced Egfr signaling in adenoma
formation.
Lrig1/ Duodenal Adenomas Exhibit Gastric
Metaplasia
To further elucidate the molecular underpinnings of Lrig1/
duodenal adenomas, we performed gene expression proﬁling
of the adenomas compared with adjacent normal tissue. In
addition to increased expression of Areg, Btc, and Muc6, we1129
Figure 7 A subset of human duodenal tumors
exhibits features of LRIG1/ adenomas. A and B:
Hematoxylin and eosin (H&E) staining of a repre-
sentative human duodenal adenoma and adeno-
carcinoma displaying neoplastic cuboidal-shaped
foveolar cells. The lesions exhibit gastric meta-
plasia as determined by MUC6 (C and D) and
MUC5AC (E and F) staining, along with increased
amphiregulin (AREG) (G and H) and ERBB2 (I and
J) immunoreactivity. Boxed regions are magniﬁed
in insets (2.5). Scale bars: 100 mm.
Wang et alobserved signiﬁcant up-regulation of the gastric-speciﬁc
markers Muc5ac, Gkn1, and trefoil factor 1 (Tff1)
(Figure 6, A and B, and Supplemental Table S2). Expression
of these gastric-speciﬁc genes was validated by RT-qPCR
(Figure 6C). Lrig1/ adenomas were predominantly
composed of cuboidal-shaped epithelial cells resembling
foveolar cells from the normal stomach that were Cdx2
negative (Figure 6, D and E) but positive for Muc5ac
(Figure 6F) and Gkn1 (Figure 6G), further supporting that
these adenomas exhibit gastric metaplasia. Of note, tubular
adenomas distal to Brunner glands (Supplemental Figure S1,
BeD) exhibited immunoreactivity for the intestinal-speciﬁc
marker Cdx2 (Figure 6D and Supplemental Figure S2A).
Characterization of Gastric Metaplasia in a Subset of
Human Duodenal Carcinomas
The World Health Organization has divided duodenal/
ampullary carcinomas into two major groups (intestinal type1130and pancreatobiliary type) and ﬁve minor variants.24 While
reviewing duodenal/ampullary cancers from our institution,
we identiﬁed a subset of periampullary duodenal tumors
with dysplastic Brunner glands and gastric-type foveolar
cells but negative CDX2 immunoreactivity (data not
shown). We identiﬁed ﬁve duodenal cancers and three ad-
enomas with these features. Similar to LRIG1/ adenomas,
we detected immunoreactivity for the gastric mucins MUC6
and MUC5AC in cuboidal neoplastic cells resembling
gastric foveolar cells (Figure 7, AeF), indicating gastric
metaplasia. These human tumors were also positive for
AREG (Figure 7, G and H), ERBB2 (Figure 7, I and J), and
p-EGFR (Figure 8, A and D), suggesting that heightened
ERBB signaling may contribute to the pathogenesis of these
tumors. Note that adjacent normal tissue from an adenoma
and an adenocarcinoma exhibited minimal immunoﬂuores-
cence (Supplemental Figure S3, B and C). Of note, LRIG1
immunoreactivity was not detected in dysplastic regions
(Figure 8, B and E) but was present in adjacent normal areasajp.amjpathol.org - The American Journal of Pathology
Loss of Lrig1 Leads to Duodenal Adenomas(Figure 8, C and F) and in normal human duodenum
(Supplemental Figure S4). The signiﬁcance of LRIG1
staining in the stroma is uncertain. The speciﬁcity of the
anti-LRIG1 antibody was validated by overexpression of
enhanced green ﬂuorescent proteinetagged LRIG1
(Supplemental Figure S5). Thus, we have described a new
subset of human duodenal tumors containing not only his-
tologic features of Brunner glands and gastric metaplasia but
also positive immunoreactivity for MUC6, MUC5AC,
AREG, ERBB2, and p-EGFR and negative immunoreac-
tivity for LRIG1, similar to Lrig1/ duodenal adenomas.Discussion
We previously reported that 14 of 16 Lrig1/ mice (88%)
developed duodenal adenomas.18 We herein extended these
studies to 54 Lrig1/ mice and showed that duodenal ade-
nomas occurred in 49 (91%). These ﬁndings reinforce the
earlier observation that loss of Lrig1 results in a highly
penetrant adenoma phenotype and support our contention
that Lrig1 acts as a tumor suppressor in vivo. In addition, we
investigated the molecular pathogenesis of these adenomasFigure 8 Human duodenal tumors exhibit enhanced epidermal growth facto
(AeC) and an adenocarcinoma (DeF) (histologic features are shown in Figure 7,
negative for LRIG1 (B and E) immunoreactivity in dysplastic regions. Adjacent
exhibited LRIG1 immunoreactivity. Scale bars: 100 mm.
The American Journal of Pathology - ajp.amjpathol.organd found that they exhibit gastric metaplasia. We propose
that loss of the pan-ErbB negative regulator Lrig1 results in
increased total Egfr and p-Egfr and, in this context, pre-
disposes to neoplasia. We identiﬁed a subset of human
duodenal tumors in the periampullary region that have fea-
tures of Lrig1/ duodenal tumors, including histologically
abnormal Brunner glands (hyperplastic or dysplastic), gastric
metaplasia, enhanced EGFR activity, and loss of LRIG1.
Brunner glands secrete mucus to protect the duodenal
mucosa from acidic and noxious contents,20 and they produce
growth factors, such as EGF21,22 and TGFA,23 to stimulate
mucosal growth. We detected growth factors, such as Areg
(Supplemental Figure S2, C and D) and p-Egfr (Supplemental
Figure S2, E and F), in Brunner glands, suggesting that active
Egfr signaling can support Brunner gland growth in a cell-
autonomous manner. In addition, we did not observe any
difference in proliferation (Supplemental Figure S2, G and H)
or p-Egfr (Supplemental Figure S2, E and F) in the duodenal
crypts above the Brunner glands, indicating that the overlying
epithelium is less likely to contribute to increased proliferation
at 4 and 5 weeks of age (Figure 2C) and increased Brunner
gland size at 2 months of age (Figure 2D). Because Lrig1 is
expressed in both compartments (Figure 4A), we cannotr receptor (EGFR) activity and loss of LRIG1. A human duodenal adenoma
A and B, respectively) that were positive for p-EGFR(pY1068) (A and D) but
normal (Adj NL) areas from an adenoma (C) and an adenocarcinoma (F)
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Figure 9 Schematic of a two-compartment model for duodenal ade-
noma formation after loss of Lrig1. A: Under normal physiologic conditions,
Lrig1 maintains quiescence of progenitor cells in Brunner glands and
overlying epithelium by suppressing ErbB signaling. B: When Lrig1 is lost,
there is increased proliferation of Brunner glands at 4 to 5 weeks of age.
This enhanced proliferation results in expansion of Brunner glands by 2
months of age. The enlarged Brunner gland compartment leads to increased
local production of the epidermal growth factor receptor (Egfr) ligands
amphiregulin (Areg) and betacellulin (Btc). C: Excess Egfr ligands signal to
both compartments and predispose to adenoma formation.
Wang et aldeﬁnitively determine the compartment from which the tu-
mors initiate. It is also possible that loss of Lrig1 in both
compartments cooperates in adenoma formation. Further
experimentation using compartment-speciﬁc driver mouse
models is needed to address this issue.
During human embryonic development, MUC5AC is
expressed in Brunner glands by 18 weeks of gestation, but it
is lost and replaced by MUC6 by 24 weeks; this pattern of
expression persists in adults.25 Although the precise etiol-
ogy is debatable,25e27 a central element of gastric metaplasia
in duodenal tissue is inﬂammation, often due to surface
ulceration and the subsequent reparative events.25,27e29 In
response to inﬂammation, a reparative lineage in the mucosa
differentiates into gastric foveolar-like cells.25 This damage
response recapitulates a Brunner gland developmental pro-
gram, during which TFF1 and MUC5AC are expressed.25
Whether the reparative lineage that gives rise to gastric
metaplasia arises from the crypt base25 or Brunner glands27,30
remains to be determined.1132It is thought that inﬂammation and ulceration can result in
EGFR activation.31,32 On genetic ablation of Lrig1, Egfr is
activated without antecedent inﬂammation, and we did not
observe ulceration or inﬂammation in Lrig1/ duodenal
adenomas. In Lrig1 null mice, total Egfr and other ErbB
receptors were increased in grossly normal intestine
compared with wild-type intestine,18 consistent with the role
of Lrig1 in the down-regulation of ErbBs.10,33e35 In addi-
tion, enhanced Egfr signaling results in transcriptional up-
regulation of Egfr and its ligands (Figure 5, A and B).
Thus, by Lrig1 ablation, Egfr circumvents negative regula-
tion; it becomes activated, thereby bypassing inﬂammation-
associated Egfr activation. This ultimately predisposes to
adenoma formation.
Based on these ﬁndings, we propose a two-compartment
model in which Lrig1 acts to maintain stem cell quiescence
by suppressing levels of Egfr (Figure 9). In the event of
Lrig1 loss, Egfr levels increase. Persistent proliferation due
to loss of Lrig1 leads to expansion of Brunner glands. The
increase in glandular mass results in increased production of
the Egfr ligands Areg and Btc. These Egfr ligands act on
Egfr and other ErbBs in the overlying epithelium, predis-
posing to neoplasia with features of gastric metaplasia.
Studies are under way to assess the requirement of Egfr in
Lrig1/ duodenal tumorigenesis using Egfr conditional
knockout mice (Egfrﬂ/ﬂ).
Human duodenal carcinomas are uncommon, accounting
for approximately 1% of digestive cancers,30 although most
small-bowel carcinomas occur in the duodenum.36 Most of
these cases are diagnosed at an advanced stage,37 and there
is no effective treatment.38 The two major subtypes of
duodenal neoplasms are intestinal type and pancreatobiliary
type. Histologically, a subset of duodenal carcinomas in the
periampullary region exhibits hyperplastic or dysplastic
Brunner glands and consists of atypical cuboidal-shaped
columnar epithelial cells with a clear cytoplasm, resem-
bling gastric-foveolar cells that express MUC5AC.30 Here-
in, we identiﬁed a subset of human duodenal tumors with
dysplastic Brunner glands, gastric metaplasia, and increased
EGFR activity. In the tumors examined, LRIG1 immuno-
reactivity was lost in dysplastic regions (Figure 8, B and E)
but retained in adjacent normal mucosa (Figure 8, C and F),
as well as in normal duodenum (Supplemental Figure S4),
suggesting that loss of LRIG1 may contribute to the path-
ogenesis of this tumor type. However, note that there are
many ways to increase ERBB activity, including mutation
or ampliﬁcation of receptors, increased EGFR ligands, and
loss of negative regulators. Thus, multiple pathogenic
mechanisms other than loss of LRIG1 could result in
enhanced EGFR activity, ultimately leading to cancer.Acknowledgments
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